Revelation Biosciences, Inc. (REVBW)San Diego, United States | NasdaqCM
0.01 USD
+0.00
(1.020%)
⇧
(July 13, 2026, 3:46 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:02 a.m. EDT
The security is trading at a fraction of its book value due to severe fundamental deterioration, making it a high-risk speculative vehicle rather than an investment. The company is burning through cash aggressively, with operating and free cash flows deeply in the negative, while returning equity to shareholders via massive buybacks that are eroding the balance sheet further. There is no dividend income to offset the capital destruction, and the lack of any price history prevents assessing a long-term trend, leaving the outlook entirely dependent on a turnaround that current metrics do not support. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 5.844 |
| Beta | -0.12 |
| Website | https://www.revbiosciences.com |
| Attribute | Value |
|---|---|
| Address1 | 4,660 La Jolla Village Drive |
| Address2 | Suite 100 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | -0.117 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 3.323 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0099 |
| Current Ratio | 10.024 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0099 |
| Day Low | 0.0064 |
| Debt To Equity | 5.844 |
| Display Name | Revelation Biosciences |
| Ebitda | -10,041,287 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -4.773 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0099 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0064 |
| Fifty Two Week Low Change | 0.0035 |
| Fifty Two Week Low Change Percent | 0.54687506 |
| Fifty Two Week Range | 0.0064 - 0.0099 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 3,436,361 |
| Free Cashflow | -5,157,217 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California. |
| Long Name | Revelation Biosciences, Inc. |
| Market | us_market |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_696222591 |
| Net Income To Common | -21,504,760 |
| Open | 0.0125 |
| Operating Cashflow | -8,690,025 |
| Operating Margins | 0.0 |
| Phone | 650 800 3717 |
| Previous Close | 0.0098 |
| Price Hint | 4 |
| Price To Book | 0.0029792357 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.959 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00009999983 |
| Regular Market Change Percent | 1.0204064 |
| Regular Market Day High | 0.0099 |
| Regular Market Day Low | 0.0064 |
| Regular Market Day Range | 0.0064 - 0.0099 |
| Regular Market Open | 0.0125 |
| Regular Market Previous Close | 0.0098 |
| Regular Market Price | 0.0099 |
| Regular Market Time | 1,783,972,000 |
| Regular Market Volume | 35,704 |
| Return On Assets | -0.66188 |
| Return On Equity | -1.24408 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | CA |
| Symbol | REVBW |
| Total Cash | 14,113,415 |
| Total Cash Per Share | 3.611 |
| Total Debt | 759,044 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.773 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 35,704 |
| Website | https://www.revbiosciences.com |
| Zip | 92,122 |